[{"id":"a86fead0-6d68-4e5e-8342-7224d15b5ca0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04994626","created_at":"2021-08-06T12:53:05.326Z","updated_at":"2024-07-02T16:36:26.846Z","phase":"Phase 2","brief_title":"Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies","source_id_and_acronym":"NCT04994626","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" CD20 • MYD88 • CD79B • CD79A","pipe":" | ","alterations":" CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation","tags":["CD20 • MYD88 • CD79B • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2021-08-06"}]